Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo

被引:200
作者
Cai, LP
Yin, JP
Starovasnik, MA
Hogue, DA
Hillan, KJ
Mort, JS
Filvaroff, EH
机构
[1] Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Pathol, S San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Prot Engn, S San Francisco, CA 94080 USA
[4] Shriners Hosp Children, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada
关键词
cartilage; cytokines; interleukins; rheumatoid arthritis; T lymphocytes;
D O I
10.1006/cyto.2001.0939
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Overexpression of interleukin (IL-)17 has recently been shown to be associated with a number of pathological conditions. Because IL-17 is found at high levels in the synovial fluid surrounding cartilage in patients with inflammatory arthritis, the present study determined the direct effect of IL-17 on articular cartilage. As shown herein, IL-17 was a direct and potent inducer of matrix breakdown and an inhibitor of matrix synthesis in articular cartilage explants. These effects were mediated in part by leukemia inhibitory factor (LIF), but did not depend on interleukin-1 activity. The mechanism whereby IL-17 induced matrix breakdown in cartilage tissue appeared to be due to stimulation of activity of aggrecanase(s), not matrix metalloproteinase(s). However, IL-17 upregulated expression of matrix metalloproteinase(s) in chondrocytes cultured in monolayer. In vivo, IL-17 induced a phenotype similar to inflammatory arthritis when injected into the intra-articular space of mouse knee joints. Furthermore, a related protein, IL-17E, was found to have catabolic activity on human articular cartilage. This study characterizes the mechanism whereby IL-17 acts directly on cartilage matrix turnover. Such findings have important implications for the treatment of degenerative joint diseases such as arthritis. (C) 2001 Academic Press.
引用
收藏
页码:10 / 21
页数:12
相关论文
共 45 条
[1]
Aarvak T, 1999, J IMMUNOL, V162, P1246
[2]
CYTOKINES AND CYTOKINE INHIBITORS OR ANTAGONISTS IN RHEUMATOID-ARTHRITIS [J].
AREND, WP ;
DAYER, JM .
ARTHRITIS AND RHEUMATISM, 1990, 33 (03) :305-315
[3]
INHIBITION OF THE PRODUCTION AND EFFECTS OF INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR-ALPHA IN RHEUMATOID-ARTHRITIS [J].
AREND, WP ;
DAYER, JM .
ARTHRITIS AND RHEUMATISM, 1995, 38 (02) :151-160
[4]
Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage [J].
Attur, MG ;
Patel, RN ;
Abramson, SB ;
Amin, AR .
ARTHRITIS AND RHEUMATISM, 1997, 40 (06) :1050-1053
[5]
Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO
[6]
2-2
[7]
PRODUCTION OF LEUKEMIA INHIBITORY FACTOR BY HUMAN ARTICULAR CHONDROCYTES AND CARTILAGE IN RESPONSE TO INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR-ALPHA [J].
CAMPBELL, IK ;
WARING, P ;
NOVAK, U ;
HAMILTON, JA .
ARTHRITIS AND RHEUMATISM, 1993, 36 (06) :790-794
[8]
Chabaud M, 1999, ARTHRITIS RHEUM-US, V42, P963, DOI 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO
[9]
2-E
[10]
Chabaud M, 1998, J IMMUNOL, V161, P409